Gara Jalqabaatti › Leukemia Myeloidii Hamaa › North Carolina › Durham
Qorannoo klinikaalii Leukemia Myeloidii Hamaa Durham, NC keessatti
Qorannoo 33 Leukemia Myeloidii Hamaa f Durham fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
- Durham VA Medical Center, Durham
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2
- Duke University Medical Center, Durham
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Namoota walitti qabaa jiraSadarkaa 2
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · Miili 10 fagaatti
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2
- Duke University Medical Center, Durham
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2
- Duke University Medical Center, Durham
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2
- Duke University Medical Center, Durham
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Namoota walitti qabaa jiraSadarkaa 3
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · Miili 10 fagaatti
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Namoota walitti qabaa jiraSadarkaa 1/2
- Duke University Medical Center, Durham
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
Namoota walitti qabaa jiraSadarkaa 1
- University of North Carolina at Chapel Hill, Chapel Hill · Miili 10 fagaatti
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Namoota walitti qabaa jiraSadarkaa 1/2
- UNC School of Medicine, Division of Hematology, Chapel Hill · Miili 10 fagaatti
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Namoota walitti qabaa jiraSadarkaa 3
- US-Chapel Hill-UNCNORTHCAROLINA, Chapel Hill · Miili 10 fagaatti
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
Namoota walitti qabaa jiraSadarkaa 1
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · Miili 10 fagaatti
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Namoota walitti qabaa jiraSadarkaa 1/2
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · Miili 10 fagaatti
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Namoota walitti qabaa jiraSadarkaa 3
- Duke University Medical Center, Durham
- University of North Carolina, Chapel Hill, Chapel Hill · Miili 10 fagaatti
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
Namoota walitti qabaa jiraSadarkaa 1
- University of North Carolina at Chapel Hill, Chapel Hill · Miili 10 fagaatti
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Namoota walitti qabaa jiraSadarkaa 1/2
- Research Site, Durham
- Research Site, Chapel Hill · Miili 10 fagaatti
Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
Namoota walitti qabaa jiraSadarkaa 2
- University of North Carolina at Chapel Hill, Chapel Hill · Miili 10 fagaatti
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Namoota walitti qabaa jiraQorannoo ilaalaa
- Duke University Medical Center, Durham
- University of North Carolina at Chapel Hill, Chapel Hill · Miili 10 fagaatti
A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
Namoota walitti qabaa jira
- University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill · Miili 10 fagaatti
Registry of Older Patients With Cancer
Namoota walitti qabaa jiraQorannoo ilaalaa
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · Miili 10 fagaatti
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
Namoota walitti qabaa jiraSadarkaa 2
- UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill · Miili 10 fagaatti
A Study of Revumenib and Mezigdomide in People With Leukemia
Namoota walitti qabaa jiraSadarkaa 1/2
- University of North Carolina (Data Collection Only), Chapel Hill · Miili 10 fagaatti
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
Namoota walitti qabaa jiraSadarkaa 1
- UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill · Miili 10 fagaatti
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Namoota walitti qabaa jiraSadarkaa 1
- University of North Carolina, Chapel Hill · Miili 10 fagaatti
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Namoota walitti qabaa jiraSadarkaa 2/3
- Duke University, Durham
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Namoota walitti qabaa jiraSadarkaa 1/2
- Duke University, Durham
- UNC Hospital, Chapel Hill · Miili 10 fagaatti
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Namoota walitti qabaa jiraSadarkaa 2
- University of North Carolina, Chapel Hill · Miili 10 fagaatti
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Namoota walitti qabaa jiraSadarkaa 1
- Duke Blood Cancer Center, Durham
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Namoota walitti qabaa jiraSadarkaa 1
- Duke Cancer Center, Durham
Novel Digital Application for Patients With Acute Leukemia
Namoota walitti qabaa jira
- Duke University, Durham
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Namoota walitti qabaa jiraQorannoo ilaalaa
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · Miili 10 fagaatti
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Namoota walitti qabaa jiraSadarkaa 1/2
- Duke University Medical Center, Durham
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
- Duke University, Durham
- University of North Carolina at Chapel Hill, Chapel Hill · Miili 10 fagaatti
Qorannoo Leukemia Myeloidii Hamaa magaalota biroo keessatti
- Houston, TXQorannoo 85
- New York City, NYQorannoo 51
- Boston, MAQorannoo 44
- Baldwin Park, CAQorannoo 40
- Seattle, WAQorannoo 40
- Columbus, OHQorannoo 35
- Philadelphia, PAQorannoo 34
- Atlanta, GAQorannoo 30
- Tampa, FLQorannoo 29
- Chicago, ILQorannoo 26
- Portland, ORQorannoo 25
- Miami, FLQorannoo 24
Qorannoo biroo Durham keessatti
- Saree OljooQorannoo 63
- Saree (Gosoota Hunda)Qorannoo 58
- Kansara Qara'a Non-Small CellQorannoo 39
- Myeloma Baay’eeQorannoo 37
- Kansara MetastatikiiQorannoo 33
- Dhibee QaraQorannoo 32
- Kansarii ProstateQorannoo 32
- Kansarii ColorectalQorannoo 28
- Luukemiya Limfoositiikii KeessummaaQorannoo 27
- Kansarii OvariiQorannoo 27
- Cufama OnneeQorannoo 26
- Kansarii PancreasQorannoo 24
Kanneen ClinicalTrials.gov irraa argaman, daataa 05-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.